- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04901884
PET/MR Pre- og Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
Undersøkende evaluering av samtidig hjerte-PET/MR, metabolomiske markører og sirkulerende DNA som mulige prognostiske markører for å identifisere pasienter som utvikler forbigående eller permanente kardiopulmonale dysfunksjoner etter strålebehandling
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.
PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).
Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.
To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
RT is a well-known and established therapy or adjuvant therapy for the treatment of thoracic malignancies (breast cancer, lung cancer, lymphoma and others). It usually uses high energy radiation from x-rays, gamma rays or other charged particles to induce DNA damage in malignant cells. Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, the signs and symptoms of radiation induced cardiopulmonary dysfunction (RICPD) still persist. However, in the majority of cases, it remains unclear which cardiopulmonary damage is the main /leading cause for the clinical symptoms the patients are experiencing.
Hybrid PET/MRI is a promising technique that allows for truly simultaneous molecular, anatomic and functional imaging of the cardiopulmonary system. The simultaneity is an important aspect in this proposed study since only parameters measured at the same time in PET and MR can be used for an integrated, multimodality parameter for possible detection and prognostication of the different underlying processes of cardiopulmonary dysfunction after RT. Furthermore, certain PET-uptake of the RV have to be corrected for RV mass which is only possible with concomitant anatomical imaging. MR imaging and PET at different time point are not accurately reflective of the underlying pathophysiological pathways and metabolic state at the specific time points pre- and post radiotherapy. To our knowledge, there are no online publications of its use in the diagnosis and prognostication of cardiopulmonary dysfunction after RT and specifically PH.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Patrick Veit-Haibach, MD
- Telefonnummer: 6085 416-340-4800
- E-post: Patrick.Veit-Haibach@uhn.ca
Studer Kontakt Backup
- Navn: Andrew Hope, MD
- Telefonnummer: 416-946-2124
- E-post: Andrew.Hope@rmp.uhn.ca
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- University Health Network
-
Ta kontakt med:
- Patrick Veit-Haibach
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥18 years
- Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy
- Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.
- A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age.
- Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).
Exclusion Criteria:
- Contraindication for MR as per current institutional guidelines.
- Contraindication for Gadolinium injection as per current institutional guidelines.
- Inability to lie supine for at least 45 minutes.
- Any patient who is pregnant or breastfeeding.
- Any patient with known hypersensitivity to 18F-FDG.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: One arm / exploratory study
Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours. |
(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of FDG uptake of heart
Tidsramme: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of the left and right ventricles of heart will be measured and compared in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of FDG uptake of lungs
Tidsramme: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of left and right ratios within the lungs in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the heart function
Tidsramme: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
MRI of ventricular volumes in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the lung perfusion
Tidsramme: before radiotherapy and up to 16 weeks after completion of radiotherapy
|
Percentage of the perfused/ventilated lung segments will be evaluated and compared pre and post therapy by SPECT scans |
before radiotherapy and up to 16 weeks after completion of radiotherapy
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Patrick Veit-Haibach, MD, University Health Network, Toronto
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 18-5879
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .